The Precautionary Principle is the idea that if an action has a suspected risk of harm, the burden of proof rests on those advocating the action to prove it is not harmful. It sounds reasonable when stated this way. In practice it has become a weapon used against every beneficial intervention whose risks have not yet been completely mapped, and the cost of its deployment is measured in lives. Max More, the philosopher who coined the term transhumanism as a modern movement, proposed an alternative in 2005. He called it the Proactionary Principle. The Proactionary Principle says that the costs of not acting must be weighed against the costs of acting, and that the default under genuine uncertainty is not paralysis but calibrated action.
Let me show you what is wrong with the Precautionary Principle by walking through the cases where it has been invoked. It was invoked against genetically modified crops, on the grounds that the full ecological effects were not yet mapped. The invocation delayed adoption of Golden Rice, a beta-carotene-enhanced variant that would have addressed vitamin A deficiency in children in low-income countries. The delay is measured in the millions. Children who would not have died of vitamin A deficiency if Golden Rice had been deployed when it was ready died of vitamin A deficiency while the Precautionary Principle was being invoked against the variety. The invocation did not produce more safety. It produced more deaths. The deaths were diffuse and the regulators who delayed the technology were never held accountable, because the principle that caused the deaths was never required to count them.
It was invoked against nuclear power, on the grounds that the full risks of accidents and waste were not completely mapped. The invocation resulted in the scaling back of nuclear programs across Europe and the United States over the past forty years. The counterfactual is extensive. A world in which the nuclear expansion of the 1970s had continued on its original trajectory would have produced substantially lower carbon emissions, substantially lower coal-related deaths from air pollution, and a different climate trajectory. The actual number of deaths from nuclear accidents in the history of civilian power is in the thousands. The number of deaths from coal pollution over the same period is in the millions. The Precautionary Principle was applied asymmetrically — strictly against nuclear, loosely against coal — and the asymmetry resulted in a catastrophic policy error that is still playing out.
It was invoked against gene therapy for healthy individuals. The FDA's posture on enhancement applications, informed by the Precautionary Principle, has kept a large space of interventions in regulatory limbo despite decades of research. The official justification is that the long-term risks are not completely characterized. This is true. It will always be true, because long-term risks cannot be fully characterized without long-term use, which cannot happen until regulatory approval, which cannot happen until long-term risks are characterized. The loop is self-perpetuating. The Precautionary Principle, applied this way, locks the loop. The therapies stay in limbo indefinitely, while the conditions they would address continue to produce suffering that was never entered into the ledger.
It was invoked against aging research itself. Until very recently, the NIH declined to fund proposals that named aging as the primary target, on the grounds that aging is not a disease and that interventions might have unpredictable effects. The position has been slowly breaking down over the past decade — the TAME trial with metformin is the most prominent counterexample — but the decades during which aging research was systematically underfunded are real, and the cost is real. Every year of delay in aging research is a delay in the therapies that will emerge from it. The delay is paid for by the people who age in the meantime, which is everyone.
The Proactionary Principle flips the default. Under the Proactionary Principle, inaction is not neutral. Inaction has costs. The costs are usually diffuse, delayed, and distributed across a large population, which makes them easy to overlook. But they are real. When an intervention would produce a genuine benefit, refusing to deploy it transfers the cost of the refusal onto whoever would have benefited. The regulator who delays the therapy is not being safe. They are making a decision that people will die during the delay. The principle just requires that both sides of the ledger get counted.
Here is the specific formal statement of the Proactionary Principle, as Max More proposed it. People's freedom to innovate technologically is highly valuable, even critical, to humanity. This implies a range of responsibilities for those considering whether and how to develop, deploy, or restrict new technologies. Assess risks and opportunities according to available science, not popular perception. Account for both the costs of the restrictions themselves, as well as the foregone benefits. Favor measures that are proportionate to the probability and magnitude of impacts, and that have the highest expected value. The principle does not abandon caution. It requires that caution be applied symmetrically, to both the risks of action and the risks of inaction.
Now this is the part where opponents of the Proactionary Principle try to score cheap points. They say the principle is a corporate talking point, a cover for releasing dangerous products into the wild without proper testing, a justification for moving fast and breaking things. The framing is a caricature. The Proactionary Principle does not argue against safety testing. It argues that safety testing should be calibrated to the magnitude of the risk, that risks of action should be balanced against risks of inaction, and that the default under uncertainty should be to assess and proceed rather than to pre-emptively forbid. The principle is more demanding than the Precautionary Principle, not less, because it requires counting costs that the Precautionary Principle hides.
The asymmetry of how these principles get applied is the single most important observation in this whole domain. The Precautionary Principle is applied strictly to new technologies and loosely to existing ones. A new drug has to prove its safety to an extremely high standard before entering the market. An existing drug, even one with known and serious side effects, faces a much lower bar to stay on the market. A new food additive has to go through years of review. An additive already in the food supply when the review process was set up grandfathered in. A novel procedure faces skepticism. A traditional procedure with comparable risks faces none. The asymmetry produces a systematic bias toward the status quo, even when the status quo is actively harmful.
Let me give you the clearest example of this asymmetry in action. The status quo of human aging kills approximately 100,000 people per day worldwide. That number does not refer to aging as a contributing cause. That is the number of deaths directly attributable to age-related disease each day. A therapy that could reduce that number by even 10% would save roughly 10,000 lives per day. The Precautionary Principle is applied with full force to any proposed aging intervention. It is applied with essentially zero force to the aging process itself. The asymmetry is grotesque. The aging process is not subjected to the question, is its ongoing operation justified, given the harms it causes. It is treated as a given. Only interventions against it are treated as requiring justification. That is not symmetric precaution. That is a bias toward one specific form of harm.
The same asymmetry applies to a dozen other interventions. The status quo of cardiovascular disease kills millions per year. Interventions against it face rigorous scrutiny. The disease itself is treated as natural and therefore exempt from the ledger. The status quo of cognitive decline in late life produces enormous suffering. Interventions against it face regulatory walls. The decline itself is treated as the baseline against which interventions are measured, rather than as a harm requiring its own justification. The pattern is consistent. The Precautionary Principle, as actually deployed, treats any deviation from the current biological baseline as requiring justification, while treating the current biological baseline as acceptable by default.
This is wrong even on the Precautionary Principle's own terms. If we are supposed to be precautionary about potential harms, the harms produced by doing nothing have to count. They usually are not counted. The person who dies of a preventable condition because the preventive therapy has been tangled in regulatory review for fifteen years is not an accident. They are a cost of the regulatory posture. The posture is not free. It is paid for by those who die during the delay. A symmetric precautionary calculation would add up those deaths and compare them to the deaths that would have resulted from deploying the therapy with less review. The symmetric calculation is almost never performed. The asymmetric calculation is the default, and the default is systematically biased toward the harms of inaction.
Now let me make the practical case. The individual response to the Precautionary Principle, applied to your own health, is to not let it make your decisions for you. The bureaucratic reflex is to treat any intervention that has not been approved by the relevant authorities as too risky to consider. This reflex is wrong in both directions. Some approved interventions are harmful. Some unapproved interventions are safe. The evidence base for each intervention is what matters, not the regulatory status. Regulatory status is a filter that has been calibrated for the average case, and you are not the average case. You are a specific person with specific goals, specific risk tolerance, and specific information about your own biology. You can evaluate interventions against your own parameters.
This is not a license to be reckless. The Proactionary Principle, applied at the individual level, requires rigorous assessment. Read the primary literature. Understand the mechanism. Model the expected effect size and the variance. Assess the known risks against the expected benefits. Make the decision with a clear picture of the tradeoff. Most people have never done this for any health decision. They outsource the decision to their doctor, and their doctor outsources the decision to FDA-approved options. The chain of outsourcing is comfortable and it leaves most of the available benefit on the table. The benefit is captured by the people who do their own assessment and make their own decisions.
The Proactionary Principle at the civilizational level is harder because it requires institutions, not just individuals. It requires regulatory agencies that count the costs of delay as well as the costs of action. It requires funding bodies that treat the ongoing operation of the status quo as a harm to be addressed, not as a neutral baseline. It requires a culture that is as suspicious of inaction as it is of action. We do not have any of those institutions yet. They would be a political project. The political project has barely started. But individual action does not have to wait for the institutional change. You can operate on the Proactionary Principle right now in your own life.
Step back and look at the actual situation. The Precautionary Principle, applied asymmetrically, has become one of the largest sources of preventable harm in modern society. It delays interventions that would save lives. It protects the status quo against challenge even when the status quo is actively harmful. It gives regulatory bureaucracies permission to be slow without counting the cost of the slowness. The Proactionary Principle fixes this by requiring that both sides of the ledger get counted. The ledger is not complicated. The costs of action and the costs of inaction both exist. Both belong in the calculation. Counting only one is not caution. It is a systematic error that kills people. We are the species which modifies itself, and the species that refuses to modify itself is the species that accepts the ongoing toll of the unmodified baseline, which is the largest toll on the table.